{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:36:43Z","timestamp":1786653403010,"version":"build-2736575974"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Saudi J Gastroenterol"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/1319-3767.170947","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T04:01:20Z","timestamp":1449201680000},"page":"345","source":"Crossref","is-referenced-by-count":2,"title":["The new era of hepatitis C virus therapy"],"prefix":"10.4103","volume":"21","author":[{"given":"Bandar","family":"Al-Judaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1319-3767.170947-1","first-page":"107","volume-title":"Evolving epidemiology of hepatitis C virus","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key-10.4103\/1319-3767.170947-2","first-page":"558","volume-title":"Global epidemiology of hepatitis C virus infection","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"key-10.4103\/1319-3767.170947-3","first-page":"1447","volume-title":"Is screening baby boomers for HCV enough.A call to screen for hepatitis C virus in persons from countries of high endemicity?","author":"Asselah","year":"2014","journal-title":"Liver Int"},{"key":"key-10.4103\/1319-3767.170947-4","first-page":"17","volume-title":"Natural history of hepatitis C","author":"Alberti","year":"1999","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.170947-5","first-page":"344","volume-title":"Systematic review: Outcome of compensated cirrhosis due to chronic hepatitis C infection","author":"Alazawi","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/1319-3767.170947-6","first-page":"2886","volume-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"key-10.4103\/1319-3767.170947-7","first-page":"459","volume-title":"Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections","author":"Kobayashi","year":"2006","journal-title":"J Med Virol"},{"key":"key-10.4103\/1319-3767.170947-8","first-page":"1276","volume-title":"Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis","author":"Toshikuni","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.4103\/1319-3767.170947-9","first-page":"349","volume-title":"Epidemiology of viral hepatitis in Saudi Arabia: Are we off the hook?","author":"Abdo","year":"2012","journal-title":"Saudi J Gastroenterol","ISSN":"https:\/\/id.crossref.org\/issn\/1319-3767","issn-type":"print"},{"key":"key-10.4103\/1319-3767.170947-10","first-page":"989","volume-title":"Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors?","author":"Alswaidi","year":"2010","journal-title":"J Epidemiol Community Health"},{"key":"key-10.4103\/1319-3767.170947-11","first-page":"10","volume-title":"HCV genotypes among 1013 Saudi nationals: A multicenter study","author":"Al","year":"2013","journal-title":"Ann Saudi Med","ISSN":"https:\/\/id.crossref.org\/issn\/0256-4947","issn-type":"print"},{"key":"key-10.4103\/1319-3767.170947-12","first-page":"323","volume-title":"Liver transplantation in patients with hepatocellular carcinoma: A single-center experience","author":"Azzam","year":"2011","journal-title":"Exp Clin Transplant"},{"key":"key-10.4103\/1319-3767.170947-13","first-page":"e7612","volume-title":"Clinical characteristics of patients with hepatocellular carcinoma in a middle eastern population","author":"Alswat","year":"2013","journal-title":"Hepat Mon"},{"key":"key-10.4103\/1319-3767.170947-14","first-page":"984","volume-title":"Liver transplantation for hepatitis C from donation after cardiac death donors: An analysis of OPTN\/UNOS data","author":"Uemura","year":"2012","journal-title":"Am J Transplant"},{"key":"key-10.4103\/1319-3767.170947-15","first-page":"889","volume-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"key-10.4103\/1319-3767.170947-16","first-page":"223","volume-title":"Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: A retrospective review","author":"Wells","year":"2013","journal-title":"Saudi J Gastroenterol","ISSN":"https:\/\/id.crossref.org\/issn\/1319-3767","issn-type":"print"},{"key":"key-10.4103\/1319-3767.170947-17","first-page":"243","volume-title":"Burden of disease and cost of chronic hepatitis C infection in Canada","author":"Myers","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"key-10.4103\/1319-3767.170947-18","first-page":"392","volume-title":"EASL Clinical Practice Guidelines: Management of hepatitis C virus infection","author":"European","year":"2014","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.170947-19","first-page":"1","volume-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"key-10.4103\/1319-3767.170947-20","first-page":"293","volume-title":"SASLT practice guidelines for the management of hepatitis C virus infection: Summary of recommendations","author":"Alghamdi","year":"2012","journal-title":"Saudi J Gastroenterol","ISSN":"https:\/\/id.crossref.org\/issn\/1319-3767","issn-type":"print"},{"key":"key-10.4103\/1319-3767.170947-21","unstructured":"Recommendations for Testing, Managing, and Treating Hepatitis C. Available from: http:\/\/www.hcvguidelines.org. [Last accessed on 2015 Jan 3]."},{"key":"key-10.4103\/1319-3767.170947-22","first-page":"615","volume-title":"Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party.Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection","author":"McCaughan","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.4103\/1319-3767.170947-23","first-page":"60","volume-title":"SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection","author":"Alghamdi","year":"2015","journal-title":"Saudi J Gastroenterol","ISSN":"https:\/\/id.crossref.org\/issn\/1319-3767","issn-type":"print"},{"key":"key-10.4103\/1319-3767.170947-24","first-page":"260","volume-title":"Ribavirin-free treatment may soon be a reality","author":"Al-Judaibi","year":"2015","journal-title":"Saudi J Gastroenterol","ISSN":"https:\/\/id.crossref.org\/issn\/1319-3767","issn-type":"print"},{"key":"key-10.4103\/1319-3767.170947-25","first-page":"48","volume-title":"New developments in HCV therapy","author":"Kronenberger","year":"2012","journal-title":"J Viral Hepat"},{"key":"key-10.4103\/1319-3767.170947-26","first-page":"403","volume-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"key-10.4103\/1319-3767.170947-27","first-page":"1483","volume-title":"ION-2 Investigators.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-28","first-page":"359","volume-title":"An update on the management of hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver","author":"Myers","year":"2012","journal-title":"Can J Gastroenterol"},{"key":"key-10.4103\/1319-3767.170947-29","first-page":"1195","volume-title":"SPRINT-2 Investigators.Boceprevir for untreated chronic HCV genotype 1 infection","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-30","first-page":"2405","volume-title":"ADVANCE Study Team.Telaprevir for previously untreated chronic hepatitis C virus infection","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-31","first-page":"1014","volume-title":"ILLUMINATE Study Team.Response-guided telaprevir combination treatment for hepatitis C virus infection","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-32","first-page":"2417","volume-title":"REALIZE Study Team.Telaprevir for retreatment of HCV infection","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-33","first-page":"1207","volume-title":"HCV RESPOND-2 Investigators.Boceprevir for previously treated chronic HCV genotype 1 infection","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-34","doi-asserted-by":"crossref","unstructured":"Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial. Gastroenterology 2014;146:1669-79.e3.","DOI":"10.1053\/j.gastro.2014.02.051"},{"key":"key-10.4103\/1319-3767.170947-35","first-page":"414","volume-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"key-10.4103\/1319-3767.170947-36","first-page":"1878","volume-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-37","first-page":"1756","volume-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"key-10.4103\/1319-3767.170947-38","first-page":"1889","volume-title":"ION-1 Investigators.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-39","first-page":"1879","volume-title":"ION-3 Investigators.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-40","unstructured":"Gilead Sciences Inc. Product Monograph: Harvoni (Ledipasvir\/Sofosbuvir) Tablets 90 mg\/400 mg Antiviral Agent Gilead Sciences Inc; 2015. Available from: http:\/\/www.gilead.ca\/pdf\/ca\/harvoni_pm_english.pdf. [Last accessed on 2015 Jan 3]."},{"key":"key-10.4103\/1319-3767.170947-41","unstructured":"Wyles D, Pockros P, Zhu Y, Jenny C, Flamm S. Retreatment of Patients Who Failed Prior Sofosbuvir-Based Regimens with All Oral Fixed-Dose Combination Ledipasvir\/Sofosbuvir Plus Ribavirin for 12 Weeks American Association for the Study of Liver Diease. Boston: American Association for the Study of Liver Diease; 2014."},{"key":"key-10.4103\/1319-3767.170947-42","first-page":"13","volume-title":"Ledipasvir\/sofosbuvir fixed-dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy","author":"Bourliere","year":"2014","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.170947-43","doi-asserted-by":"crossref","unstructured":"Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Jr., et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep;149(3):649-59.","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"key-10.4103\/1319-3767.170947-44","first-page":"211","volume-title":"AI444040 Study Group.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-45","first-page":"435","volume-title":"Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacy","author":"Asselah","year":"2014","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.170947-46","first-page":"1597","volume-title":"HALLMARK-DUAL Study Team.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"key-10.4103\/1319-3767.170947-47","first-page":"501","volume-title":"Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1","author":"Izumi","year":"2014","journal-title":"Antivir Ther"},{"key":"key-10.4103\/1319-3767.170947-48","first-page":"1594","volume-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-49","first-page":"1973","volume-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-50","first-page":"1286A","volume-title":"C-SWIFT: Grazo- previr (MK-5172) + Elbasvir (MK-8742) + sofosbuvir in treatment-naive patients with hepatitis C Virus Genotype 1 Infection, with and without cirrhosis, for durations of 4, 6, or 8 Weeks (Interim Results)","author":"Lawitz","year":"2014","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.170947-51","first-page":"564","volume-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.J Hepatol","author":"Forns","year":"2015","journal-title":""},{"key":"key-10.4103\/1319-3767.170947-52","unstructured":"Roth D. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patietns with heptitis C virus genotype 1 infection and chronic kidney disease (C-SUPFER).: European Association for the Study of the Liver (EASL); 2015."},{"key":"key-10.4103\/1319-3767.170947-53","first-page":"1246","volume-title":"STARTVerso1 Study Group.STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon\/ribavirin for chronic HCV genotype-1 infection","author":"Ferenci","year":"2015","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.170947-54","first-page":"958","volume-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"key-10.4103\/1319-3767.170947-55","first-page":"1993","volume-title":"VALENCE Investigators.Sofosbuvir and ribavirin in HCV genotypes 2 and 3","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-56","first-page":"1867","volume-title":"POSITRON Study; FUSION Study.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-3767.170947-57","first-page":"769","volume-title":"Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.170947-58","first-page":"S46","volume-title":"Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir + GS-5816 for 12 weeks in treatment naive patients with genotype 1-6 HCV patients (Abstract)","author":"Everson","year":"2014","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.170947-59","first-page":"1418","volume-title":"Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT2\/3 study (Abstract)","author":"Dore","year":"2013","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.170947-60","first-page":"22","volume-title":"High Efficacy of LDV\/SOF Regimens for 12 Weeks for Patients with HCV Genotype 3 or 6 Infection","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.170947-61","first-page":"1127","volume-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype3 infection: ALLY-3 phase III study","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.170947-62","first-page":"65","volume-title":"Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients","author":"Peter","year":"2015","journal-title":"Liver Int"},{"key":"key-10.4103\/1319-3767.170947-63","first-page":"24","volume-title":"Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs.PEG-IFN alfa 2b; the debate continues","author":"Esmat","year":"2014","journal-title":"Liver Int"},{"key":"key-10.4103\/1319-3767.170947-64","first-page":"533A","volume-title":"Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon Alfa-2a and ribavirin in treatmentnaive HCV-genotype 1 or 4 patients: Phase 2b COMMAND- 1 SVR12 results","author":"Hezode","year":"2012","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.170947-65","first-page":"948","volume-title":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection.Gut","author":"Hezode","year":"2015","journal-title":""},{"key":"key-10.4103\/1319-3767.170947-66","first-page":"1204","volume-title":"A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection","author":"Hassanein","year":"2015","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.170947-67","first-page":"S535","volume-title":"Once-daily simeprevir (TMC435) with peginterferon\/ribavirin in treatment- nai\u0131ve or treatment-experienced chronic HCV genotype-4 infected patients: Final results of a phase III trial","author":"Moreno","year":"2014","journal-title":"J Hepatol"},{"key":"key-10.4103\/1319-3767.170947-68","first-page":"1129A","volume-title":"Interferon-free regimens of ombitasvir and ABT-450\/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results","author":"Pol","year":"2014","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.170947-69","first-page":"581","volume-title":"Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.J Hepatol","author":"Doss","year":"2015","journal-title":""},{"key":"key-10.4103\/1319-3767.170947-70","first-page":"321A","volume-title":"All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: Interim results from the NIAID SYNERGY Trial","author":"Kapoor","year":"2014","journal-title":"Hepatology"},{"key":"key-10.4103\/1319-3767.170947-71","unstructured":"European Commission Grants Marketing Authorization for Gilead's Harvoni \u00ae\u25be (Ledipasvir\/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4. 2015. Available from: http:\/\/www.gilead.com\/news\/press-releases\/2014\/11\/european-commission-grants-marketing-authorization-for-gileads-harvoni-ledipasvirsofosbuvir-the-first-single-tablet-regimen-to-treat-the-majority-of-chronic-hepatitis-c-patients-with-genotype-1-and-4. [Last accessed on 2015 July 15]."},{"key":"key-10.4103\/1319-3767.170947-72","first-page":"1","volume-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection: A randomized trial","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/1319-3767.170947-73","first-page":"514","volume-title":"Antiviral activity and resistance of HCV NS5A replication complex inhibitors","author":"Gao","year":"2013","journal-title":"Curr Opin Virol"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:36:39Z","timestamp":1786649799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-3767.170947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"alternative-id":["170947"],"URL":"https:\/\/doi.org\/10.4103\/1319-3767.170947","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}